News

Published on 20 May 2023 on Simply Wall St. via Yahoo Finance

Regeneron Pharmaceuticals' (NASDAQ:REGN) investors will be pleased with their solid 158% return over...


Article preview image

When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, if you buy shares in a high quality company at the right price, you can gain well over 100%. For example, the Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) share price has soared 158% in the last half decade. Most would be very happy with that. In the last week the share price is up 2.0%.

With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies.

Check out our latest analysis for Regeneron Pharmaceuticals

NASDAQ.REGN price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Regeneron stock defended at RBC after DOJ suit (NASDAQ:REGN)

Regeneron (REGN) stock remains a buying opportunity, RBC Capital Markets said, after the Departme...

Seeking Alpha 11 Apr 2024

DOJ files complaint against Regeneron over Eylea Medicare pricing (NASDAQ:REGN)

The DOJ has filed a complaint against Regeneron (REGN) alleging the drugmaker fraudulently inflat...

Seeking Alpha 10 Apr 2024

Regeneron Pharma falls after US government alleges fraud

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) faced a blow in early trading after being hit with fr...

Proactive Investors 10 Apr 2024

An Intrinsic Calculation For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Suggests It's 47%...

Key Insights Regeneron Pharmaceuticals' estimated fair value is US$1,774 based on 2 Stage Free Ca...

Simply Wall St. via Yahoo Finance 10 Apr 2024

Sanofi and Regeneron’s Dupixent set for large gains with likely COPD approval

Dupixent from Sanofi and Regeneron Pharmaceuticals is expected to gain approval for COPD, which...

Seeking Alpha 1 Apr 2024

Is Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Stock's Recent Performance A Reflection Of Its...

Most readers would already know that Regeneron Pharmaceuticals' (NASDAQ:REGN) stock increased by ...

Simply Wall St. via Yahoo Finance 30 Mar 2024

Petri Dish: NIH sends BioNTech notice of default; Intellia ends Regeneron deal - Boston Business...

In today’s Petri Dish we’ll cover why Replimune Group is shaking up its C-suite, how BioNTech is...

The Business Journals 28 Mar 2024

Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates

It was a busy week for the biotech sector, with lots of study data readouts and regulatory update...

Zacks via Yahoo Finance 28 Mar 2024

Should You Invest in the iShares Biotechnology ETF (IBB)?

Launched on 02/05/2001, the iShares Biotechnology ETF (IBB) is a passively managed exchange trade...

Zacks via Yahoo Finance 28 Mar 2024

Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, ...

Simply Wall St. via Yahoo Finance 26 Mar 2024